Optimal use of Bone-Targeted Agents in Breast Cancer
Jacob, A.; Mathew, A.
Oncology 30(8): 703-704
2016
ISSN/ISBN: 0890-9091 PMID: 27528239 Document Number: 686669
Document emailed within 1 workday
Related Documents
Jerzak, K.J.; Raphael, J.; Desautels, D.N.; Blanchette, P.S.; Tyono, I.; Pritchard, K.I. 2018: Bone-Targeted Therapy in Early Breast Cancer Oncology 32(11): 562-569Tongyoo, A. 2010: Targeted therapy: novel agents against cancer Journal of the Medical Association of Thailand 93(Suppl 7): S311-S323
Zissimopoulos, A.; Stellos, K.; Matthaios, D.; Petrakis, G.; Parmenopoulou, V.; Babatsikou, F.; Matthaiou, E.; Theodosiadou, E.; Hountis, P.; Koutis, C. 2009: Type i collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy Journal of Buon: Official Journal of the Balkan Union of Oncology 14(3): 463-472
Tenner, L.L.; O'Neil, B.H. 2014: Colorectal cancer and molecular targeted agents: progress--with caveats Oncology 28(2): 125; 128
Kato, S. 2013: New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(1): 6-9
Furuta, M.; Yokota, T. 2018: The Combination of Molecular Targeted Agents with Radiotherapy in Head and Neck Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(3): 419-423
Deshpande, H.A.; Gettinger, S.N.; Sosa, J.A. 2010: Targeted therapy for thyroid cancer: An updated review of investigational agents Current Opinion in Investigational Drugs 11(6): 661-668
Abdulrahman Jnr, G.O. 2015: Targeted therapies in the management of breast cancer Gulf Journal of Oncology 1(19): 38-43
Tirelli, U.; Berretta, M.; Bearz, A.; Carbone, A. 2011: Grouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis European Review for Medical and Pharmacological Sciences 15(11): 1355-1356
Sendur, M.A.N.; Aksoy, S.; Demirci, S.; Ozdemir, N.Y.; Zengin, N.; Altundag, K. 2014: Can targeted programmed death-1 antibody be a new treatment approach in breast cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 19(2): 584
Lehr, H.-A.; Schaefer, S.C.; Delaloye, J.-F.ço. 2009: Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer Revue Medicale Suisse 5(211): 1525-1529
Okano, M.; Ohtake, T.; Saji, S. 2016: Combination Therapy of Molecular-Targeted Drugs for Breast Cancer -- their Potential in the Future Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(4): 398-403
2011: Categorization of triple-negative breast cancer patients will help in targeted therapy selection Oncology 25(9): 849
Taguchi, T. 2011: Encounter of cancer cells with bone. Treatment of bone metastases from breast cancer Clinical Calcium 21(3): 429-438
Ormenisan, C.; Kubik, M.; Legrand, S.; Kraemer, D.; Smotherman, C.; Masood, S. 2015: The potential of ki67 and p53 assessment in development of individualized targeted therapy in breast cancer patients Pathologica 107(3-4): 177-180
Benz, C.; Tillis, T.; Tattelman, E.; Cadman, E. 1982: Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer Cancer Research 42(5): 2081-2086
Guan, H-tao.; Xue, X-huan.; Wang, X-jing.; Li, A.; Qin, Z-yin. 2006: Effects of siRNA targeted to survivin in suppressing proliferation and inducing apoptosis in breast cancer MCF-7 cells Zhonghua Zhong Liu Za Zhi 28(5): 326-330
Taguchi, T. 2018: Bone and calcium metabolism associated with malignancy. Clinical Characteristics and Treatment of Cancer Treatment Induced Bone Loss(CTIBL)in Breast Cancer Clinical Calcium 28(11): 1515-1517
Siegel, M.B.; Van Swearingen, A.E.D.; Anders, C.K. 2014: Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis Oncology 28(7): 579; 584-585
MJ Seibel; M Koeller; B van der Velden; I Diel 2002: Markers of Bone Turnover Do Not Predict Bone Metastases in Breast Cancer Clinical Laboratory 48(11-12): 583-588